Gazette.govt.nzPursuant to section 23(4A) of the Medicines Act 1981, the Minister of Health hereby renews the provisional consent to the sale, supply or use in New Zealand of the medicines set out in the Schedule hereto:
Schedule
| Product: | Trandate |
| Active Ingredient: | Labetalol hydrochloride 100mg |
| Dosage Form: | Film coated tablet |
| New Zealand Sponsor: | Pharmacy Retailing (NZ) Limited t/a Healthcare Logistics |
| Manufacturer: | Aspen Pharma Pty Limited, Melbourne, Australia |
|
Note: This consent is given subject to the following condition: The medicine may only be marketed or distributed when no other labetalol hydrochloride tablet medicine with consent under section 20 of the Medicines Act 1981 is available in the New Zealand market, or to meet PHARMAC supply obligations. |
|
| Note: This renewed consent is valid for two years from 19 March 2024. | |
| Product: | Trandate |
| Active Ingredient: | Labetalol hydrochloride 200mg |
| Dosage Form: | Film coated tablet |
| New Zealand Sponsor: | Pharmacy Retailing (NZ) Limited t/a Healthcare Logistics |
| Manufacturer: | Aspen Pharma Pty Limited, Melbourne, Australia |
|
Note: This consent is given subject to the following condition: The medicine may only be marketed or distributed when no other labetalol hydrochloride tablet medicine with consent under section 20 of the Medicines Act 1981 is available in the New Zealand market, or to meet PHARMAC supply obligations. |
|
| Note: This renewed consent is valid for two years from 19 March 2024. | |
Dated this 4th day of March 2024.
CHRIS JAMES, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).